Budesonide oral suspension - Shire

Drug Profile

Budesonide oral suspension - Shire

Alternative Names: Oral viscous budesonide; SHP 621

Latest Information Update: 24 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Verus Pharmaceuticals
  • Developer Shire
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Eosinophilic oesophagitis

Most Recent Events

  • 24 Oct 2018 Budesonide oral suspension is still in phase III trials for Eosinophilic esophagitis in USA (NCT03245840) (Shire pipeline, October 2018)
  • 04 Oct 2017 Shire initiates enrolment in a phase III extension trial for Eosinophilic oesophagitis (In children, In adolescents, In adults) in USA (NCT03245840)
  • 16 Aug 2017 Shire plans a phase III extension trial for Eosinophilic oesophagitis (in children, In adolescents, In adults) (NCT03245840)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top